ATR and neoplasm: Berzosertib (formerly M6620, VX-970) is an intravenous (i.v.), highly potent (IC50 = 19 nM), and selective, first-in-class ATR inhibitor.12 Preclinical studies of berzosertib have shown synergy in combination with cisplatin, which led to anti-tumour responses in patient-derived lung cancer xenografts that were otherwise insensitive to cisplatin monotherapy.12 The timing of berzosertib administration relative to chemotherapy is critical as preclinical investigations have shown that optimal efficacy is achieved by administering berzosertib 12–24 h after cisplatin.13